By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has completed the acquisition of Celera for around $671 million.

The Madison, NJ-based lab testing firm said that it completed the deal through a short-form merger after its tender offer expired last week. Each share of Celera common stock was converted into the right to receive the same $8 in cash, without interest and less any withholding of taxes, that was paid in the tender offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.